PL378212A1 - Inhibitory 3-hydroksylazy kynureninowej do leczenia cukrzycy - Google Patents

Inhibitory 3-hydroksylazy kynureninowej do leczenia cukrzycy

Info

Publication number
PL378212A1
PL378212A1 PL378212A PL37821203A PL378212A1 PL 378212 A1 PL378212 A1 PL 378212A1 PL 378212 A PL378212 A PL 378212A PL 37821203 A PL37821203 A PL 37821203A PL 378212 A1 PL378212 A1 PL 378212A1
Authority
PL
Poland
Prior art keywords
kynurenine
diabetes
treatment
hydroxylase inhibitors
hydroxylase
Prior art date
Application number
PL378212A
Other languages
English (en)
Inventor
Valerie Autier
De Vacqueur Annick Arbellot
Gérard Moinet
Dominique Marais
Catherine Kargar
Micheline Kergoat
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0300107A external-priority patent/FR2849599B1/fr
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL378212A1 publication Critical patent/PL378212A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL378212A 2003-01-07 2003-12-18 Inhibitory 3-hydroksylazy kynureninowej do leczenia cukrzycy PL378212A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0300107A FR2849599B1 (fr) 2003-01-07 2003-01-07 Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete
FR0314263A FR2849598B1 (fr) 2003-01-07 2003-12-04 Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans

Publications (1)

Publication Number Publication Date
PL378212A1 true PL378212A1 (pl) 2006-03-20

Family

ID=32598906

Family Applications (2)

Application Number Title Priority Date Filing Date
PL03376017A PL376017A1 (pl) 2003-01-07 2003-12-18 Inhibitory 3-hydroksylazy kynureninowej do leczenia cukrzycy poprzez zwiększanie liczby wysepek komórek Langerhansa
PL378212A PL378212A1 (pl) 2003-01-07 2003-12-18 Inhibitory 3-hydroksylazy kynureninowej do leczenia cukrzycy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL03376017A PL376017A1 (pl) 2003-01-07 2003-12-18 Inhibitory 3-hydroksylazy kynureninowej do leczenia cukrzycy poprzez zwiększanie liczby wysepek komórek Langerhansa

Country Status (17)

Country Link
US (2) US20060052456A1 (pl)
EP (2) EP1581215B1 (pl)
JP (2) JP2006515594A (pl)
KR (2) KR20050090447A (pl)
AR (2) AR043327A1 (pl)
AT (1) ATE457725T1 (pl)
AU (2) AU2003293937B2 (pl)
BR (2) BR0317947A (pl)
CA (2) CA2512563C (pl)
DE (1) DE60331359D1 (pl)
ES (1) ES2339656T3 (pl)
FR (1) FR2849598B1 (pl)
MX (2) MXPA05007293A (pl)
PL (2) PL376017A1 (pl)
RU (2) RU2005125086A (pl)
TW (2) TW200418820A (pl)
WO (2) WO2004060368A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2849598B1 (fr) * 2003-01-07 2006-09-22 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
WO2008022281A1 (en) * 2006-08-16 2008-02-21 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Small molecule inhibitors of kynurenine-3-monooxygenase
WO2008022286A2 (en) 2006-08-16 2008-02-21 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Small molecule inhibitors of kynurenine-3-monooxygenase
US20100273872A1 (en) * 2007-12-03 2010-10-28 Valerie Autier Use of 4-oxobutanoic acid derivatives in the treatment of pathologies associated with immunological disorders
EP2254568B1 (en) * 2008-03-12 2017-06-07 University of Miami Compound that activates an ampa/kainate type receptor for treating hypoglycemia
PL228037B1 (pl) * 2009-03-23 2018-02-28 Marciniak Agnieszka Maria Zastosowanie kwasu kynureninowego w zapobieganiu lub leczeniu chorób trzustki
EP2521558A4 (en) 2009-12-30 2013-07-03 Avon Prod Inc TOPICAL LIGHTING COMPOSITION AND USES THEREOF
EP3915367A1 (en) 2010-08-18 2021-12-01 BioSplice Therapeutics, Inc. Diketones and hydroxyketones as catenin signaling pathway activators
PE20151721A1 (es) 2013-02-22 2015-12-07 Samumed Llc Y-dicetonas como activadores de la ruta de senalizacion de wnt/b-catenina
DK3206686T3 (da) 2014-08-20 2019-12-16 Samumed Llc Gamma-diketoner til behandling og forebyggelse af ældning af huden og rynker
PT3197466T (pt) 2014-09-26 2021-05-14 Univ British Columbia Combinação de quinurenina e células apresentadoras de antígeno (apc) como agentes terapêuticos e métodos para seu uso na modulação imunológica

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181474A (en) * 1978-03-02 1980-01-01 Dunham-Bush, Inc. Vertical axis hermetic rotary helical screw compressor with improved rotary bearings and oil management
DE59310166D1 (de) * 1992-05-18 2001-05-31 Ciclomulsion Ag Cyclosporin(e) enthaltende pharmazeutische Zubereitung zur intravenösen Applikation sowie Verfahren zu ihrer Herstellung
WO1994017828A2 (en) * 1993-02-09 1994-08-18 Biogen, Inc. Treatment for insulin dependent diabetes
AU679318B2 (en) * 1993-12-22 1997-06-26 Entropy Systems, Inc. Device and method for thermal transfer using air as the working medium
GB9522615D0 (en) * 1995-11-03 1996-01-03 Pharmacia Spa 4-Phenyl-4-oxo-butanoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity
GB9522617D0 (en) * 1995-11-03 1996-01-03 Pharmacia Spa 4-Phenyl-4-oxo-butenoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity
JP3104966B2 (ja) * 1996-02-19 2000-10-30 日本たばこ産業株式会社 糖尿病治療薬
IL125820A0 (en) * 1996-02-19 1999-04-11 Japan Tobacco Inc Therapeutic agent for diabetes and a pharmaceutical composition containing the same
US5877193A (en) * 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
FR2752422B1 (fr) * 1996-08-16 1998-11-06 Lipha Composition pharmaceutique contenant des acides 4-oxo-butanoiques
US6288063B1 (en) * 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
US6572542B1 (en) * 2000-03-03 2003-06-03 Medtronic, Inc. System and method for monitoring and controlling the glycemic state of a patient
SE0001899D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
US7419670B2 (en) * 2000-09-29 2008-09-02 Viron Therapeutics, Inc. Method of treating arthritis with SERP-1 and an immunosuppressant
FR2849598B1 (fr) * 2003-01-07 2006-09-22 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
TW200920357A (en) * 2007-09-10 2009-05-16 Curis Inc HSP90 inhibitors containing a zinc binding moiety

Also Published As

Publication number Publication date
ATE457725T1 (de) 2010-03-15
MXPA05007292A (es) 2005-09-08
CA2512563C (en) 2012-06-19
US20060052456A1 (en) 2006-03-09
FR2849598B1 (fr) 2006-09-22
TW200418820A (en) 2004-10-01
RU2005125086A (ru) 2006-08-27
PL376017A1 (pl) 2005-12-12
KR20050090447A (ko) 2005-09-13
TW200503676A (en) 2005-02-01
WO2004060369A1 (en) 2004-07-22
CA2512558A1 (en) 2004-07-22
US20060142358A1 (en) 2006-06-29
WO2004060368A1 (en) 2004-07-22
RU2005125085A (ru) 2006-03-20
ES2339656T3 (es) 2010-05-24
WO2004060369A8 (en) 2005-07-07
KR20050090443A (ko) 2005-09-13
EP1581215A1 (en) 2005-10-05
AU2003293937B2 (en) 2009-03-26
MXPA05007293A (es) 2005-09-08
RU2351329C2 (ru) 2009-04-10
JP4813800B2 (ja) 2011-11-09
EP1581216A1 (en) 2005-10-05
BR0317947A (pt) 2005-11-29
FR2849598A1 (fr) 2004-07-09
JP2006516960A (ja) 2006-07-13
AU2003296679A1 (en) 2004-07-29
US7727977B2 (en) 2010-06-01
AR042712A1 (es) 2005-06-29
AR043327A1 (es) 2005-07-27
EP1581215B1 (en) 2010-02-17
AU2003293937A1 (en) 2004-07-29
BR0317950A (pt) 2005-11-29
CA2512563A1 (en) 2004-07-22
JP2006515594A (ja) 2006-06-01
DE60331359D1 (de) 2010-04-01

Similar Documents

Publication Publication Date Title
IL185485A0 (en) Use of pde7 inhibitors for the treatment of neuropathic pain
EP1789086A4 (en) PROLONGED TREATMENT OF MULTIPLE SCLEROSIS
AP2007004157A0 (en) N- (N-sulfonylaminomethyl) cyclo-propanecarboxamide derivatives useful for the treatment of pain
IL182436A0 (en) Thienopyridinone compounds and methods of treatment
CY2018006I2 (el) Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας
IL177232A0 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
IL178996A0 (en) Thienopyridinone compounds and methods of treatment
PL378762A1 (pl) Leczenie nadmiernego zanikania rozpływnego kości związkami indolinonowymi
ATE457725T1 (de) Kynurenine 3-hydroxylase inhibitoren zur behandlung von diabetes
PL1811866T3 (pl) Zastosowanie związków przeciwutleniających przy uszkodzeniach mięśni
ZA200707147B (en) Use of PDE7 inhibitors for the treatment of neuropathic pain
IL172018A0 (en) Enalapril-nitroxyderivatives derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases
PL1959957T3 (pl) Pochodne pirymidyloaminobenzamidu do leczenia neurowłókniakowatości
EP1750698A4 (en) 5-ANILINO-4-HETEROARYLPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES
IS7970A (is) PDE4-hemlar til að meðhöndla eitlafrumuæxli
GB0400802D0 (en) Compounds for the treatment of disease
GB0415181D0 (en) Compounds for use in the treatment of infection
GB0426196D0 (en) Methods of treatment
IL178907A0 (en) Use of sulglicotide for the treatment of mucositis
PL1727545T3 (pl) Zastosowanie pochodnych N-piperydyny do leczenia patologii neurodegeneracyjnych
ZA200605302B (en) Use of pentadienoic acid derivatives for the treatment of hyperuricemia
ZA200600494B (en) Reduction of the concentration of undesired compounds
GB0423173D0 (en) Treatment of diabetes
ZA200606780B (en) Compounds for the treatment of diseases
ZA200608015B (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)